ReviewJournal of community hospital internal medicine perspectives2022
Extracorporeal Liver Support: An Updated Review of Mechanisms and Current Literature.
Review in Journal of community hospital internal medicine perspectives, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 14 citations in OpenAlex.
- Liver Xenotransplantation: From Early Primate Trials to the First-in-Human Porcine Bridging Therapies.Journal of clinical medicine · 2026Review
- Cast nephropathy in the ICU: Early recognition and extracorporeal strategies to improve outcomes.Journal of intensive medicine · 2026Review
- Plasma Adsorption Perfusion (BR-350) Versus Open Albumin Dialysis (OPAL) for Hyperbilirubinemia in Hepatic Failure in Cirrhotic Patients.Artificial organs · 2026Article
- Low-Volume Plasma Exchange for Fulminant Hepatic Failure Secondary to Hepatitis A in a Young Adult: A Case Report.Clinical case reports · 2026Article
- Management of acute liver failure-an updated literature review.World journal of critical care medicine · 2025Review
- Blood Purification in Hepatic Dysfunction after Liver Transplant or Extensive Hepatectomy: Far from the Best-Case Scenarios.Journal of clinical medicine · 2024Article
- Recent Advances in Liver Tissue Engineering as an Alternative and Complementary Approach for Liver Transplantation.Current issues in molecular biology · 2023Review
- Extracorporeal adsorption of protective and toxic bile acids and bilirubin in patients with cholestatic liver dysfunction: a prospective study.Annals of intensive care · 2023Article
- Roquin-1 resolves sepsis-associated acute liver injury by regulating inflammatory profiles via miRNA cargo in extracellular vesicles.iScience · 2023Article
- Crosslinked Bifunctional Particles for the Removal of Bilirubin in Hyperbilirubinemia Cases.Materials (Basel, Switzerland) · 2023Article
- The Use of Liver Support System Devices in Acute Liver Failure as a Consequence of Metastatic Melanoma in the Liver: A Case Report and Review of the Literature.Case reports in oncologyArticle
- The Hepato-Cardio-Renal Axis in Cirrhosis: Hemodynamic and Mechanistic Insights, Diagnostic Biomarkers, and Expanding Therapeutic Horizons.Discoveries (Craiova, Romania)Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Acute liver failure is a cause of major mortality in the United States. Although the liver possesses regenerative capabilities, liver transplantation is the mainstay of treating acute liver failure. This modality is associated with many financial and logistic challenges. In this regard, Extracorporeal Liver Support (ECLS) might help in reducing mortality as well as bridge a patient to liver transplant. In some cases, the sequelae of liver failure such as hepatic encephalopathy and multi-organ failure can be postponed long enough for the native liver to self-recover function. With this rationale, we sought to describe the mechanism of various ECLS modalities, provide an overview of the current evidence regarding its use and to highlight future advancements that could overcome hindrances in its use. Methods: A scoping review was performed using PubMed and other databases from 1990 to 2020 with the keywords: 'extracorporeal liver support', 'acute liver failure', 'acute on chronic liver failure', 'albumin dialysis', 'artificial' and 'bioartificial'. Results and conclusions: ECLS has shown significant improvements in bilirubin and urea levels. Various forms of ECLS might also reduce mortality due to liver failure. However, many complications, such as hypotension, anemia, bleeding issues, sepsis, can be anticipated. There are a few barriers to mainstream use of ECLS, such as specific design requirements and high cost that reduce the overall utility of this modality in a small group of liver transplant candidates. Furthermore, a multidisciplinary team approach is required to supervise ECLS, a luxury only available at major academic hospitals. Some advancements for overcoming these barriers include investigation of new scaffolding systems. In order to expand the usage of ECLS, clinical trials focusing on a comparison of different modalities of ECLS with renal replacement therapy in patients with liver failure should be promoted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.